DNA methylation inhibitors have anti-neoplastic effects including reactivation of tumor suppressor genes [121,178], down-regulation of oncogenes [123], reactivation of transposable elements (TE) to stimulate a “viral mimicry” immune response [179,180] and re-sensitization to chemotherapies [181] such as poly(ADP-ribose) Polymerase (PARP) inhibitors (PARPi) [182] and RNA splicing inhibitors [183] that hold clinical promise in treating BRCA1-mutated BCs. This evidence concerns the gene BRCA1 and neoplasm.